| References |
| 1 |
Canadian Pharmacists Association.
|
| 2 |
Cerner Multum, Inc. "Australian Product Information.".
|
| 3 |
Cerner Multum, Inc. "UK Summary of Product Characteristics.".
|
| 4 |
Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908. [PMID: 12885102]
|
| 5 |
Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80.
|
| 6 |
Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7. [PMID: 3492908]
|
| 7 |
Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5. [PMID: 6970886]
|